Finalization of Purchase Price Allocation for the Acquisition of the Quinoxyfen Business

「Upon finalizing this provisional accounting treatment, a significant revision to the initial allocation of the purchase price was reflected in the comparative information included in the quarterly consolidated financial statements for the nine months ended 31 December. As ¥6,010 million was allocated to intangible assets and other assets, the provisionally calculated amount of goodwill decreased by ¥6,010 million from ¥6,335 million to ¥325 million.」